Alfredo Carrato

Anti-VEGF therapy: a new approach to colorectal cancer therapy.

Capecitabine plus oxaliplatin for the treatment of colorectal cancer.

Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.

Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.

Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies.

Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

A Label Free Disposable Device for Rapid Isolation of Rare Tumor Cells from Blood by Ultrasounds.

Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs.

Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.

A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.

Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.

Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus.

Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments.